1. Home
  2. KALA vs VCIG Comparison

KALA vs VCIG Comparison

Compare KALA & VCIG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KALA
  • VCIG
  • Stock Information
  • Founded
  • KALA 2009
  • VCIG 2013
  • Country
  • KALA United States
  • VCIG Malaysia
  • Employees
  • KALA N/A
  • VCIG N/A
  • Industry
  • KALA Biotechnology: Pharmaceutical Preparations
  • VCIG Diversified Commercial Services
  • Sector
  • KALA Health Care
  • VCIG Consumer Discretionary
  • Exchange
  • KALA Nasdaq
  • VCIG Nasdaq
  • Market Cap
  • KALA 26.2M
  • VCIG 22.5M
  • IPO Year
  • KALA 2017
  • VCIG 2023
  • Fundamental
  • Price
  • KALA $0.81
  • VCIG $2.10
  • Analyst Decision
  • KALA Buy
  • VCIG
  • Analyst Count
  • KALA 3
  • VCIG 0
  • Target Price
  • KALA $31.50
  • VCIG N/A
  • AVG Volume (30 Days)
  • KALA 1.3M
  • VCIG 1.0M
  • Earning Date
  • KALA 11-07-2025
  • VCIG 10-06-2025
  • Dividend Yield
  • KALA N/A
  • VCIG N/A
  • EPS Growth
  • KALA N/A
  • VCIG N/A
  • EPS
  • KALA N/A
  • VCIG 5.34
  • Revenue
  • KALA N/A
  • VCIG $32,903,041.00
  • Revenue This Year
  • KALA N/A
  • VCIG N/A
  • Revenue Next Year
  • KALA N/A
  • VCIG N/A
  • P/E Ratio
  • KALA N/A
  • VCIG $0.42
  • Revenue Growth
  • KALA N/A
  • VCIG 24.77
  • 52 Week Low
  • KALA $0.77
  • VCIG $2.17
  • 52 Week High
  • KALA $20.60
  • VCIG $4,644.00
  • Technical
  • Relative Strength Index (RSI)
  • KALA 26.24
  • VCIG 32.95
  • Support Level
  • KALA $0.77
  • VCIG $2.17
  • Resistance Level
  • KALA $1.52
  • VCIG $3.49
  • Average True Range (ATR)
  • KALA 0.10
  • VCIG 0.62
  • MACD
  • KALA 0.31
  • VCIG -0.25
  • Stochastic Oscillator
  • KALA 4.56
  • VCIG 0.60

About KALA KALA BIO Inc.

Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

About VCIG VCI Global Limited

VCI Global Ltd is a holding company. The principal activities of the Company and its subsidiaries are the provision of business Strategy consultancy and technology development. The firm organized its consulting services into three main segments: Business Strategy Consultancy; Technology development, solutions and consultancy; and Others. It derives the majority of its revenue from the Business Strategy Consultancy segment, which focuses on listing solutions, investor relations, and boardroom strategies consultancy.

Share on Social Networks: